AbbVie Inc. (ABBV) is set to report its third-quarter earnings on Wednesday, with analysts expecting strong results. The company recently acquired Aliada Therapeutics, bolstering its Alzheimer’s research portfolio. We analyze AbbVie’s technical setup and analyst forecasts to see what lies ahead for the stock.
A new study suggests that semaglutide, the active ingredient in popular diabetes and weight-loss drugs Wegovy and Ozempic, could reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes. Researchers at Case Western Reserve University School of Medicine found that patients taking semaglutide had a significantly lower risk of developing Alzheimer’s compared to those on other diabetes medications.
Cassava Sciences has settled SEC charges related to misleading statements about its Alzheimer’s drug, simufilam. The company paid $40 million and is now focusing on the drug’s development. HC Wainwright upgraded Cassava’s stock to ‘Buy’ due to positive expectations for the upcoming clinical trial results.
A new study suggests that dronabinol, a synthetic form of THC, can effectively reduce agitation in Alzheimer’s patients, offering a potential alternative to current treatments that often come with serious side effects.
The FDA has approved Bristol Myers Squibb’s Cobenfy, an oral medication for schizophrenia in adults. Analysts predict significant potential for the drug, particularly in treating Alzheimer’s related psychosis, with projected peak sales exceeding $6 billion. However, despite its first-mover advantage, Cobenfy faces competition from AbbVie’s emraclidine, while potential side effects are also noted.
Cassava Sciences, its founder, and former executives have agreed to pay over $40 million to settle SEC charges alleging they misled investors about the results of a Phase 2 trial for their Alzheimer’s drug, simufilam. The SEC found that the company manipulated trial data to falsely suggest the drug’s effectiveness. The settlement includes penalties and bans on serving as officers or directors for certain individuals.
Cassava Sciences has announced that its Alzheimer’s drug candidate, simufilam, has successfully passed an interim safety review, allowing its ongoing Phase 3 trials to continue without changes. The Data and Safety Monitoring Board (DSMB) reviewed patient safety data from the trials and recommended no modifications. Simufilam is a novel oral drug designed to treat Alzheimer’s disease. The two Phase 3 trials, fully enrolled with over 1,900 patients, are expected to yield top-line results by the end of 2024 and mid-2025.
Alzheimer’s disease, a progressive neurological disorder, is on the rise, with cases expected to double by 2060. This alarming trend necessitates a comprehensive understanding of the disease, its impact, and advancements in treatment and prevention. This article delves into the growing burden of Alzheimer’s, its mortality rate, and discusses the latest research and management strategies, including medication, lifestyle changes, and supportive care.
Alzheimer’s disease, a debilitating brain disorder, can be influenced by lifestyle factors. This article outlines key lifestyle choices that can either increase or decrease the risk of developing Alzheimer’s, including physical activity, diet, social engagement, cognitive stimulation, sleep, stress management, smoking, alcohol consumption, and head trauma.
England cricketer Alice Davidson-Richards opens up about her experience caring for her father who suffered from Alzheimer’s disease. She discusses the challenges, the emotional toll, and the importance of raising awareness and funding for research.
